anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To grasp the moves of patients in future and to grasp the status of empty beds with the move of patients by displaying the hospital occupancy by patients at a designated time. SOLUTION: When the starting operation of data/time designation is performed, a calender window is displayed on a display unit 40. When any data is designated on the calender window, a time bar window expressing time is displayed near the designated data. When any time is designated, a control unit 10 recognizes the inputted date and time as the designated data and time, and the managing information of patients in the ward of hospital designated on the designated date and time is read from a hospital ward patient list data base 100 on the server side through a communication interface 30. The scheduled contents of move and scheduled date and time are possessed for each patient on the designated data and time closest to these designated data and time after the designated date and time, and a hospital ward patient list is extended in a memory unit 20.  The control unit 10 discriminates a date/time change, etc., and when there is another processing request, that request is executed.
Belonging to the technical field of traditional Chinese medicines, the invention relates to a traditional Chinese medicine for treatment of type II diabetes by invigorating spleen and purging turbidness. The traditional Chinese medicine is prepared from Astragalus, Codonopsis pilosula, Chinese yam, bighead atractylodes rhizome, coix seeds, Poria, rhizoma alismatis, Perrin, Rhizoma Dioscoreae Hypoglaucae Perrin, Salvia Miltiorrhiza, dried tangerine peel, chicken's gizzard-membrane, Harba Dendrolii Nobilis, hawthorn, jujubes, Lindera aggregata, and notoginseng flowers. Based on a secret prescription handed down from the inventor's ancestors, by combining the conclusion of years of clinical experience of the inventor, from the perspective of nourishing liver and invigorating kidney, promoting blood circulation to remove blood stasis, and with the ideas of treating disease from the root, nursing liver, kidney and spleen simultaneously, and dialectically using drugs to diabetic patients, the traditional Chinese medicine is obtained by repeated experiments. Thus, the traditional Chinese medicine has a unique curative effect on refractory diabetes. Through scientific compatibility of multiple drugs and comprehensive treatment, the effective drug components quickly enter a sick site and rapidly correct glycometabolic disorder. The traditional Chinese medicine provided by the invention has the advantages of quick effect, short course of treatment, high cure rate, and low cost.
The present disclosure provides therapeutic agents comprising VLA-4 (a4b1) and a4b?inhibiting agents defined herein. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA-4 inhibitor and one or more agents which interact with a chemokine receptor or chemokine receptors, and methods of use thereof. In some embodiments, the disclosed combinations may be used in a method of mobilizing hematopoietic stem cells. In some embodiments, the disclosed methods may be used in the treatment of a condition that requires the collection of hematopoietic stem cells for transfusions or in chemotherapy. The present disclosure further provides methods of treating a patient comprising administering an agent which interacts with a chemokine such as G-CSF, plerixafor, BL-8040 (Motixafortide), or Crop and VLA-4 inhibitors.
PURPOSE: Intertrochanteric fractures are treated surgically, allowing rapid weight-bearing to improve ambulation and lower complications and mortality. Subtrochanteric fractures are mechanically less stable and are traditionally treated with a non-weight approach and longer intramedullary nails. This study compared immediate weight-bearing versus limited weight-bearing and different intramedullary nail lengths regarding patient outcomes.
METHODS: We analyzed all consecutive cases of low-energy subtrochanteric fractures treated surgically at our institution between January 2016 and November 2020. One hundred and nine patients were found. We compared nail length and immediate versus delayed weight-bearing concerning the length of stay, time to painless ambulation, time to radiographic fracture union, and revision rates. Fracture severity was also examined using the Seinsheimer classification.
RESULTS: Length of stay and time to painless ambulation were shorter in the immediate weight-bearing group. Time to radiographic union and rate of complications were lower; however, they were not statistically significant. Conversely, no significant difference in revision rates was found. Regarding nail length, the length of stay was shorter, and the time to painless ambulation was faster in the short-length group. The rate of complications and time to union were similar. No difference in revision rate was found. Seinsheimer classification of the fracture did not influence the decision to allow weight-bearing or nail selection (p = 0.65).
CONCLUSIONS: This study demonstrates that immediate weight-bearing as tolerated and short intramedullary nails allow a quicker time for painless ambulation and hospitalization, with possibly fewer perioperative complications and faster radiographic union, without increasing complications.
Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and Placebo for INCAGN02390 will be administered intravenously every 2 weeks.
The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
1,260,665. Extracts of lime wood. LABORATOIRE L. LAFON. 10 July, 1969 [8 Aug., 1968], No. 37990/68. Heading A5B. An extract of lime bark and/or sapwood is prepared by (a) subjecting the bark and/or sapwood to an extraction with a non-polar solvent; (b) subjecting the bark and/or sapwood after the extraction (a) to an extraction, without heating, with an alcohol and concentrating the alcoholic extract under a pressure less than atmospheric pressure to a syrupy consistency; (c) subjecting the concentrated alcoholic extract to an extraction with ethyl or isopropyl ether after addition to water and adjustment to pH 4-5 with an acid, washing the ethereal extract with water, adjusting the resultant aqueous phase to pH 6-7 and recovering the solid components thereof. Preferably the non-polar solvent is ethyl ether, isopropyl ether or petroleum ether; the alcohol is absolute methanol or 96% ethanol, the acid is acetic acid; the aqueous phase is adjusted to pH 6-7 with an alkali metal or alkaline earth metal carbonate and filtered and evaporated at 50‹C to 70‹C or atomised to yield the therapeutically active extract. Therapeutic compositions having antispasmodic activity comprise the extract (comprising mainly fraxetine-8-glucoside, esculoside and organic acids) and a non-toxic pharmaceutically-acceptable excipient. The compositions may be administered orally in the form of sachets.
All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.
The present invention relates to a recipe and technology for preparing externally applied bone and tendon recovery cream of traditional Chinese medicines with rapid special effect. The bone and tendon recovery cream is used for treating common chronic diseases of hyperosteogeny, bone injury sequelae, closed fracture, vein varices, etc. The present invention sufficiently uses the Chinese medicine theory, and solves the basic pathogenic reasons of the diseases of hyperosteogeny, etc. Active ingredients of forty kinds of traditional Chinese medicines are sufficiently extracted, and are prepared into externally applied cream with easy use. Through the partial direct permeation, the bone and tendon recovery cream is used for promoting blood circulation, expelling clots, relieving the rigidity of muscles, activating collaterals, expelling pathogenic wind and dispelling cold. The present invention has the advantages of simple and convenient method, obvious curative effect, rapid radical therapy and no side effect.
There is lack of standardization of primary and revisional bariatric surgery compounded by a scant long-term outcome data. The treatment of inadequate weight loss, weight recidivism, and most severe technical complications after primary bariatric surgery remains refractory to non-operative treatment. Failure rates have been reported up to 20% and 35% for the morbidly obese (MO) and super obese (SO), respectively at 2 to 3 years after surgery. The indication for further surgical intervention remains controversial, as does what type of revisional procedure, both operative and endoscopic, to recommend. Furthermore, there is no standardization of the limb lengths, pouch size or the use of prosthetic reinforcement. Therefore the approach to these patients must be as individualized as their original operations. We formally analyze our experience with all laparoscopic revisional strategies for weigh regain after failed gastric bypass.
Acute kidney injury (AKI) is a frequent comorbidity of critical illness associated with poor outcome, including prolonged duration of mechanical ventilation, longer length of stay and increased mortality or progression to chronic kidney disease on the long term. The reported incidence of AKI in critically ill children and neonates varies widely between 10% and 80% depending on the diagnostic criteria. Besides a decline in renal function, also the phenomenon of augmented renal clearance (ARC) and in consequence enhanced clearance of renally eliminated drugs, is increasingly recognized in pediatric intensive care patients. Hence, accurate assessment of renal function is crucial in the intensive care population to guide therapy. But to date consensus is lacking about the reliability of common GFR estimation methods based on the endogenous renal biomarkers serum creatinine, cystatin C and betatrace protein in critical care patients. the aim of this study is to measure GFR in a reliable way by iohexol plasma clearance and evaluate the agreement between the gold standard technique iohexol plasma clearance and biomarker-based formula to estimate GFR.
Sepsis is a dysregulated response to infection that can result in life-threatening organ failure, and septic cardiomyopathy is a serious complication involving ferroptosis. Olaparib, a classic targeted drug used in oncology, has demonstrated potential protective effects against sepsis. However, the exact mechanisms underlying its action remain to be elucidated. In our study, we meticulously screened ferroptosis genes associated with sepsis, and conducted comprehensive functional enrichment analyses to delineate the relationship between ferroptosis and mitochondrial damage. Eight sepsis-characterized ferroptosis genes were identified in sepsis patients, including DPP4, LPIN1, PGD, HP, MAPK14, POR, GCLM, and SLC38A1, which were significantly correlated with mitochondrial quality imbalance. Utilizing DrugBank and molecular docking, we demonstrated a robust interaction of Olaparib with these genes. Lipopolysaccharide (LPS)-stimulated HL-1 cells and monocytes were used to establish an in vitro sepsis model. Additionally, an in vivo model was developed using mice subjected to cecal ligation and perforation (CLP). Intriguingly, low-dose Olaparib (5 mg/kg) effectively targeted and mitigated markers associated with ferroptosis, concurrently improving mitochondrial quality. This led to a marked enhancement in cardiac function and a significant increase in survival rates in septic mice (p < 0.05). The mechanism through which Olaparib ameliorates ferroptosis in cardiac and leukocyte cells post-sepsis is attributed to its facilitation of mitophagy, thus favoring mitochondrial integrity. In conclusion, our findings suggest that low-dose Olaparib can improve mitochondrial quality by accelerating mitophagy flux, consequently inhibiting ferroptosis and preserving cardiac function after sepsis.
This trial consists of 4 treatment arms: 3 LY2623091 dose levels and eplerenone. Each participant will participate in 2 treatment periods, with a minimum wash-out period of 28 days between dosing in the 2 treatment periods. Dosing days will be numbered 1-21 in each of the 2 treatment periods. Participants will receive different treatments in periods 1 and 2. Participants will be housed as inpatients during the days of the controlled diet administration and the oral potassium challenge and until at least 24 hours after its completion (Days -3 to 1; Days 19 to 22, in each treatment period). Otherwise the study will be done on an outpatient basis, with participants returning to the clinic for evaluations during each treatment period (Days 3 or 4, 7, and 14).
Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
The present invention relates to a traditional Chinese medicine used as both medicine and food for preventing and treating dysentery and a making method of the traditional Chinese medicine. The traditional Chinese medicine is prepared from Chinese medicinal plants used as both medicine and food as traditional Chinese medicine materials: common yam rhizome, gordon euryale seed, semen nelumbinis, pepper, Chinese date, chicken's gizzard-membrane, pericarpium zanthoxyli, etc. The present invention has the advantages of low production cost, no environmental pollution, adaptability to all people with different age, good mouth feel, small dosage, affirmative effect, and easy acceptance by patients. The combined medicinal materials of traditional Chinese medicines and properties simultaneously compromise function protection and coordination of the heart, lung, spleen, kidney, etc., and sufficiently embody the whole concept and advantages of the traditional Chinese medicine so as to complete medicine effects and functions to treat both manifestation and root cause of a disease, thereby realizing a very high bourn that the whole medicine properties of the traditional Chinese medicines tend to be mild and raise medicine effect mutually. Furthermore, as all the medicinal materials are legally used as both medicine and food, the effect is affirmative without toxic and side effect. The present invention is suitable for any crowds, with wide service range; the variety of used medicines and effect are simple and clear without dispute, and prescriptions are flexible and multiple, so the present invention is suitable for various states of illness with suitable medication selection, and widens the particular content and the application range of the determination of treatment based on different symptoms and signs of the traditional Chinese medicine and pharmacy.
Pneumoperitoneum during laparoscopic procedures greatly impairs splanchnic blood flow due to compression. Increased intra-abdominal pressure may elevate the diaphragm, increase intra-thoracic pressure, reduce functional residual capacity, and thus lead to atelectasis. In a collapsed lung, blood flow is decreased and reperfusion injury may subsequently occur during re-expansion of the lung. This ischemia-reperfusion injury results from the formation of reactive oxygen species (ROS), which are highly reactive intermediates of the oxygen metabolism. When there is an imbalance between ROS generation and removal by antioxidative mechanisms, oxidative stress occurs and eventually causes cellular and organ damage. Oxidative stress mediates tissue injury and may represent an important link between laparoscopy and clinical side effects. Malondialdehyde (MDA) is considered the most reliable marker of oxidative stress in the clinical setting. It is a breakdown product of lipid peroxidation in tissues. An elevated concentration of MDA reflects the level of lipid peroxidation.

Although there is abundant data comparing the effects of VCV and PCV during laparoscopic surgery, the time course of changes in oxidative stress in these two modes has not been elucidated. Therefore, the aim of this study was to compare the alterations of oxidative stress in two different ventilation modes, VCV and PCV, during gynecologic laparoscopic surgery. To this end, the investigators established a prospective randomized clinical study and measured the plasma levels of a lipid peroxidation marker at different stages.

Fifty-two patients of ASA physical status I or II were randomly assigned to receive either VCV or PCV during laparoscopic gynecologic surgery. During the operation, blood gas analysis and ventilation variables were recorded 1 minute before (T1) and 1 hour after (T2) the establishment of CO2 pneumoperitoneum in both groups. Blood samples for MDA measurement were collected at seven points: 1 minute before (T1) and 1 hour after (T2) pneumoperitoneum; at intervals of 30 minutes for 2 hours after the deflation of CO2 (T3\~T6); and 24 hours after the deflation of CO2 (T7). The samples were immediately centrifuged (1000g, 10 minutes) and the supernatants were stored at -800C until further analysis, which took place within 1 week. The investigators assessed the quality of recovery from anesthesia using a nine-item quality of recovery score (QoR Score) before operation and 24 hours after the deflation of CO2.
Patients randomized to 40 Gy in 15 fractions will receive 75 mg/m\^2 temozolomide per day for 15 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m\^2 for upto 1 year.
Wound healing is a tightly regulated process that ensures tissue repair and normal function following injury. It is modulated by activation of pathways such as the transforming growth factor-beta (TGF-β), Notch, and Wnt/β-catenin signaling pathways. Dysregulation of this process causes poor wound healing, which leads to tissue fibrosis and ulcerative wounds. The Wnt/β-catenin pathway is involved in all phases of wound healing, primarily in the proliferative phase for formation of granulation tissue. This review focuses on the role of the Wnt/β-catenin signaling pathway in wound healing, and its transcriptional regulation of target genes. The crosstalk between Wnt/β-catenin, Notch, and the TGF-β signaling pathways, as well as the deregulation of Wnt/β-catenin signaling in chronic wounds are also considered, with a special focus on diabetic ulcers. Lastly, we discuss current and prospective therapies for chronic wounds, with a primary focus on strategies that target the Wnt/β-catenin signaling pathway such as photobiomodulation for healing diabetic ulcers.
A method and system (10) for selectively removing one component of a material thereby concentrating other components of the material are disclosed. The material is cooled to below the melting temperature of the material to form a supercooled liquid phase with heat transfer plate with cooling channels (20). Ultrasonic energy from ultrasonic drivers (42) is applied to the material to form solid phase crystals of the component to be removed. These crystals are removed to leave the concentrated product. The ultrasonic energy prevents the growth of dendrites on the crystals, resulting in the formation and removal of small crystals of the component to be removed without damage to or removal of the remaining components. Methods and apparatuses for cryoprecipitation and chromatography are also disclosed.
<P>PROBLEM TO BE SOLVED: To stabilize posttransplant adhesion of hematopoietic stem cells, adhesion after transplantation, by using an HLA-concordant activated lymphocyte.  <P>SOLUTION: A posttransplant adhesion stabilizing composition of the hematopoietic stem cell is prepared by proliferating or activating the HLA-concordant lymphocyte in a mononuclear cell separated from peripheral blood or cord blood, then separating and collecting the lymphocyte, so that the composition containing the HLA-concordant activated lymphocyte as the main ingredient is obtained. Thus, the composition is widely used for preventing insufficiency of the posttransplant adhesion of hematopoietic stem cells, accelerating and treating the the adhesion, etc. Further, an amount of the composition to be administered is varied according to an age of a patient, a disease condition thereof, etc., but it is preferable that the composition is administered to a mammal, including a human, in an amount of 0.2-20 mg/kg/day as a hominization antibody. The composition is administered by an intravenous injection once a day (single administration or every-day administration), intermittently one to three times a week, or once per two or three weeks.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To provide a wound remedy agent easily mobilizing fibroblasts toward a wound tissue without fibroblast transplantation, and engrafting the fibroblasts in the wound tissue.SOLUTION: A fibroblast mobilizing agent includes a granulocyte colony-stimulating factor (G-CSF) as an active ingredient. The fibroblast mobilizing agent mobilizes fibroblasts to a wound tissue. The fibroblasts are mobilized to a heart. The heart is a heart after the onset of heart disease. The heart disease is myocardial infarction. By administering G-CSF, fibroblasts are transferred into a myocardial infarction lesion. Thus, deterioration of heart function is prevented and cardiac remodeling is improved.
After a screening visit (2 ½ hrs) to confirm eligibility for the study, all participants will receive 8 weekly, 1-hour, individual sessions therapy with a counselor. Participants will be randomly assigned, by chance, like the flip of a coin, to the therapy course they will attend. In one of the therapy courses, students are asked questions about their drinking and receive personalized feedback about it, and are taught coping skills for their depressive symptoms. In the second course, students are also taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference. So, both courses teach the same coping skills for depressive symptoms but include different levels of focus on alcohol.

Participants will also complete 2 follow-up visits, at the end of the 8 sessions and then again 4 weeks after completing treatment. These will involve filling out some questionnaires and completing a few neuropsychological tests (these questionnaires and neuropsychological tests will also be completed during the screening visit).